What Clinigen Group does

Clinigen Group plc is a UK-headquartered (Burton-on-Trent) global specialty pharmaceutical services and products company founded in 1989, operating across clinical trial supplies, managed access programs, licensed and unlicensed medicine distribution, regulatory affairs, pharmacovigilance, market access/HEOR consulting, and commercialization of an owned portfolio of niche specialty pharmaceuticals. The company serves three primary customer groups: pharmaceutical and biotech companies (across the product lifecycle from clinical development through commercialization), healthcare professionals and hospitals seeking access to hard-to-find medicines, and patient advocacy groups supporting rare-disease communities. The business spans 128+ countries through owned regional subsidiaries (Clinigen Healthcare France, Clinigen Ireland Ltd, Clinigen K.K.) and channel partnerships (Yusen Logistics in Belgium, Link Healthcare in Australia), with over 500 specialists and a logistics operation shipping approximately 6 million units annually.

Clinigen operates three interconnected service pillars plus a portfolio business. The Clinical Services pillar centers on the proprietary eCEMS clinical trial supplies management platform and adjacent services (packaging/labelling, comparator sourcing, on-demand sourcing, QP release, controlled drug handling, biological sample management). The Managed Access & Global Partnering pillar operates over 300 Early Access Programs (EAPs) and licensed/unlicensed distribution via affiliate-like partnership models, supported by the Navigate patient advocacy program and Clinigen Direct digital platform for healthcare professionals. The Lifecycle Services pillar encompasses regulatory affairs (bolstered by the 2024 acquisition of Kinesys Consulting), pharmacovigilance (expanded via the 2022 acquisition of Drug Safety Navigator Inc.), and the Centre of Excellence for Market Access, Pricing & HEOR. Clinigen also commercializes an owned pharmaceutical portfolio including Erwinase, Proleukin, Foscavir, Imukin, Gliadel, and Rezdiffra, and holds exclusive distribution rights for partner products including MaaT013 (MaaT Pharma) in Europe and PreemieFort (Prolacta Bioscience) in Japan.

Clinigen's revenue model combines professional services revenue (clinical trial supplies, regulatory affairs, pharmacovigilance, HEOR consulting, managed access programs) with licensing and distribution revenue (commercialized owned portfolio products and partner-product royalties). Pricing is bespoke and contract-based, with multi-year enterprise agreements typical for clinical services and quote-based pricing for product distribution; no public pricing tiers are disclosed. Go-to-market is enterprise field sales across regional business development teams (Africa, JAPAC, Europe, US) supplemented by channel partners and supported by industry events (CPhI), LinkedIn, and content marketing. Clinigen Group plc was previously listed on the London Stock Exchange and is subject to a recommended acquisition by Triley Bidco Limited (Triton Investment Management), taking the company private.

Name

Clinigen Group

Legal name

Clinigen Group plc

Website

https://clinigengroup.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Clinigen Group plc is a UK-based global specialty pharmaceutical services and products company serving pharmaceutical/biotech companies, healthcare professionals, and rare-disease patient advocacy groups across 128+ countries, combining clinical trial supplies, managed access programs, regulatory/HEOR consulting, and a niche owned-product portfolio under a single platform.

Ownership category

akta.pro rank

Product category

Pharmaceutical Services

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Specialty pharmaceutical services
• Clinical trial supplies
• Managed access programs
• Pharmacovigilance services
• Global pharmaceutical distribution

Headquarters

HQ city

Burton-on-trent

HQ country

United Kingdom

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Services: Clinigen generates revenue through providing clinical trial supply services, managed access programs, regulatory affairs, pharmacovigilance, and global distribution of pharmaceutical products. The company ships over 6 million units annually and serves customers in 128+ countries.
2. Licensed Product Distribution: Distribution and commercialization of licensed pharmaceutical products in specific markets, including own portfolio of specialty pharmaceuticals (Erwinase, Proleukin, Foscavir, Imukin, Gliadel, Rezdiffra)
3. Market Access & HEOR Services: Provides market access consulting, pricing strategy, and health economics outcomes research (HEOR) services to pharmaceutical and biotech clients
4. Unlicensed/Managed Access: Provides access to unlicensed medicines through managed access programs and named patient supply, enabling pre-approval access to investigational products

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Clinigen provides end-to-end clinical trial supply management, biological sample management, managed access/early access programs, and global licensed and unlicensed pharmaceutical distribution for pharmaceutical and biotech manufacturers. It also delivers lifecycle services (regulatory affairs, pharmacovigilance, market access, HEOR) and distributes an owned portfolio of specialty pharmaceutical products including Erwinase, Foscavir, Imukin, Gliadel, and Rezdiffra across 130+ countries.

Product overview

Clinigen Group is a global pharmaceutical services company operating as a unified platform-plus-services model that provides access to medicines across three pathways: clinical trials, licensed medicines, and unlicensed/early access programs. The platform consists of Clinical Services (including the eCEMS clinical trial supplies management platform, comparator sourcing, biological sample management, and global distribution), Managed Access & Global Partnering (pre-approval access programs, managed access consulting, and licensed/unlicensed global distribution), and Lifecycle Services (regulatory affairs, pharmacovigilance, market access, and HEOR). Clinigen also commercializes an owned pharmaceutical portfolio including Erwinase, Foscavir, Imukin, Proleukin, Gliadel, and Rezdiffra, and holds distribution rights for partner products including MaaT013 (MaaT Pharma's microbiome therapy) and PreemieFort (Prolacta's human milk-based fortifier). The company operates across 130+ countries through affiliates in Europe, North America, Africa, Japan, and Asia Pacific.

Differentiator

Problem solved

Functional benefit

Products and services

• eCEMS Clinical Trial Supplies Management Platform Proprietary electronic platform enabling end-to-end tracking, management, and coordination of clinical trial supply chain operations for pharmaceutical and biotech sponsors.
• Clinical Trial Supplies End-to-end clinical supply management including packaging and labelling, comparator sourcing, on-demand sourcing, global storage and distribution, clinical supply chain management, returns and reconciliation, QP services, controlled drug services, and specialty services.
• Biological Sample Management Comprehensive biological sample management services including biorepository services, biological sample logistics, and biological sample collection kits for clinical trial sponsors.
• Managed Access Programs Pre-approval and managed access programs enabling patients to access investigational medicinal products outside clinical trials before official marketing authorization, including compassionate use and expanded access pathways.
• Managed Access Consulting Expert consulting services helping pharmaceutical and biotech companies navigate early access program design, implementation, and compliance across global markets.
• Global Partnering (Licensed and Unlicensed Distribution) Comprehensive commercialization and distribution services enabling access to medicines in both licensed and unlicensed markets globally, including affiliate-like partnership models with market access, regulatory, medical, sales, marketing, and distribution services.
• Centre of Excellence for Market Access & HEOR Consulting division providing market access strategies, health economics outcomes research (HEOR), pricing strategy, and regulatory intelligence across the product lifecycle for pharmaceutical and biotech clients.
• Exploitant Services (France) Full-spectrum pharmaceutical services for the French market including Lifecycle Management of Marketing Authorization dossiers, pharmacovigilance, medical information, distribution, reimbursement dossier preparation, and sales force certification through Clinigen Healthcare France.
• Clinigen Direct Online platform for healthcare professionals to search and source hard-to-find licensed and unlicensed medicines globally.
• Erwinase Crisantaspase (L-asparaginase Erwinia chrysanthemi) pharmaceutical product for treating acute lymphoblastic leukaemia (ALL) in patients who cannot tolerate E. coli-derived asparaginase. Clinigen serves as exclusive global distributor.
• Foscavir Antiviral pharmaceutical product (foscarnet sodium) marketed by Clinigen Healthcare France under a Marketing Authorization.
• Imukin Immunotherapy pharmaceutical product (interferon gamma-1b) marketed by Clinigen Healthcare France under a Marketing Authorization.
• Gliadel Carmustine implant pharmaceutical product marketed by Clinigen Healthcare France for intracranial tumor treatment.
• Rezdiffra Pharmaceutical product (60mg/80mg/100mg film-coated tablets) for metabolic dysfunction-associated steatohepatitis (MASH), distributed via the AP2 (Accès Précoce post-AMM) early access program in France.
• Proleukin Aldesleukin pharmaceutical product for immunotherapy applications. Clinigen held distribution rights with worldwide rights for advanced melanoma partially transferred to Iovance Biotherapeutics in May 2023.
• MaaT013 / Xervyteg Microbiome ecosystem therapy product (Xervyteg) for acute Graft-versus-Host Disease, developed by MaaT Pharma. Clinigen holds European commercialization rights under a €10.5 million upfront license agreement signed in 2026.
• PreemieFort Enteral Solution World's first 100% human milk-based nutritional fortifier approved as a prescription drug for vulnerable infants (very low birth weight infants, those with congenital gastrointestinal/heart disorders, and post-surgical recovery cases). Clinigen K.K. serves as Marketing Authorization Holder and exclusive distributor in Japan.

Quantifiable outcome

• Serving customers in 128+ countries
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core and supporting.

• MaaT PharmacoreStrategic or Co-development Partner · 30 March 2026Licensing agreement for European commercialization of MaaT013 (Xervyteg®) worth €10.5 million upfront. Clinigen serves as strategic commercial partner, hosting industry symposium on steroid-refractory aGvHD management at EBMT 2026 congress.
• Prolacta BiosciencecoreStrategic or Co-development Partner · 12 February 2026Clinigen K.K. partnered with Prolacta Bioscience to obtain approval from Japan's Ministry of Health, Labour and Welfare for PreemieFort® Enteral Solution, a human milk-based nutritional fortifier. Clinigen serves as Marketing Authorization Holder and exclusive licensee for the Japanese market, enabling market access for this specialized neonatal product.
• Kinesys ConsultingcoreOthers · 31 July 2024Acquisition of Kinesys Consulting, a provider of regulatory services for pharmaceutical and biotech industries, to enhance Clinigen's regulatory affairs capabilities. The acquisition integrates Kinesys's expertise into Clinigen's Lifecycle Services division.
• Drug Safety Navigator Inc.coreOthers · 29 November 2022Acquisition of US-based pharmacovigilance service provider to expand drug safety capabilities. Integration of pharmacovigilance services for clinical and post-marketed products as part of Clinigen's broader plan to enhance its pharma service portfolio.
• Yusen LogisticssupportingChannel Partner/ Reseller/ DistributorPartnership with Yusen Logistics (Benelux) for warehouse and distribution services in Belgium, supporting EEA supply continuity post-Brexit from Keetberglaan 1, 9120 Melsele, Belgium.
• Link HealthcaresupportingChannel Partner/ Reseller/ DistributorRegional partnership for Australian market distribution through Link Healthcare website presence.

Scale indicators5 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• IQVIA: The largest global clinical CRO and life sciences services provider. Overlaps Clinigen in clinical trial supplies management, pharmacovigilance, regulatory services, and commercialization/post-launch services, and serves the same pharma/biotech customer base.
• Syneos Health: Clinical CRO with a strong commercialization and patient access arm following the defunct merger with InVentiv. Directly comparable to Clinigen's combined clinical + commercialization services model and target pharma/biotech clients.
• ICON plc: Global clinical CRO with significant lab and clinical research services. Competes for clinical trial supply, bioanalytical, and pharmacovigilance engagements from the same biotech and large pharma customers Clinigen serves.
• Almac Group: Privately held contract pharmaceutical services company with clinical trial supplies, commercial distribution, and specialty pharma product businesses. Closest peer in combining clinical supplies, biologics, and drug commercialization under one roof.
• PCI Pharma Services: Contract developer and manufacturer focusing on clinical trial supplies packaging, labeling, and global distribution as well as commercial launch services. Directly comparable clinical supplies backbone to Clinigen's clinical services offering.
• Marken (UPS Healthcare): UPS-owned clinical trial logistics and direct-to-patient supply chain specialist. Overlaps with Clinigen's clinical supply chain management, comparator sourcing, and global storage/distribution services.
• Parexel International: Mid- to large-sized clinical CRO with services spanning regulatory, pharmacovigilance, and clinical supplies. Competes for the same pharma/biotech RFPs as Clinigen's Lifecycle Services division.
• FarmaMondo: Specialist in managed access / named-patient programs and global access to unlicensed medicines. Founded by IDIS's former leader and the most direct pure-play competitor to Clinigen's flagship Managed Access Programs business.
• Worldwide Clinical Trials: Mid-sized clinical CRO focused on complex therapeutic areas and post-approval research. Overlaps with Clinigen's clinical services for biotech and specialty pharma sponsors.

Broad incumbents

• Catalent (Novo Holdings): Large contract development and manufacturing organization providing clinical supplies, biologics development, and commercial services. A broader incumbent that overlaps with Clinigen's clinical supplies and commercialization services but at much larger scale and with manufacturing depth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/clinigen-group
• Xx.com/clinigen

Revenue estimate

Valuation estimate

Number of profiles

Profiles25 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A12 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinigen Group